Hepatic fibrosis is a highly integrated dynamic process of molecules, cells, and tissues, that aims to limit liver damage in chronic liver diseases (such as alcohol abuse and viral infection), but leads to the gradual accumulation of ECM (Kong et al., 2020). The pathogenesis of liver fibrosis is primarily associated with the following three factors. First, several inflammatory factors, including platelet-derived growth factor, transforming growth factor-beta (TGF-β), and some chemokines, are released after liver injury, activating cell proliferation, migration, and ECM secretion, and promoting the transdifferentiation of mesenchymal cells into myofibroblasts. Second, in the healthy liver, the synthesis and degradation of ECM are precisely regulated, and thus the liver content is in dynamic equilibrium. In contrast, in chronic liver injury, HSCs synthesize a large amount of ECM and secrete matrix metalloproteinase (MMP) inhibitors [including tissue inhibitors of metalloproteinases (TIMPs)] to interfere with ECM degradation, resulting in homeostasis imbalance, ECM remodeling, and liver fibrosis (Ren et al., 2019). Lastly, HSCs and Kupffer cells settled in the liver or fibroblasts, pericytes, and epithelial cells derived from the bone marrow are transdifferentiated into myofibroblasts to repair the injured liver (Xu et al., 2014), in which HSC activation is the main source of myofibroblasts.

HSCs not only coordinate ECM deposition in the injured liver, but also are the main effectors of liver inflammation (Gao et al., 2020). HSCs are static in the physiological state and located in the perisinusoidal space. HSCs metabolize and store 80% of the body’s vitamin A, MMPs, and their inhibitors TIMPs, and express cytokines and receptors, which play an important role in vitamin A metabolism, regulation of ECM homeostasis and remodeling, and regulation of hepatocyte regeneration (Ren et al., 2019). In the process of liver fibrosis, HSCs transdifferentiate into proliferative, migratory, and contractile myofibroblasts referred to as activated HSCs, that exhibit the secretory characteristics of fibrotic cells (Tsuchida and Friedman, 2017). Various pro-fibrogenic factors released after liver injury, such as TGF-β, interleukin (IL)-6, IL-17, and connective tissue factors, directly stimulate the activation and proliferation of HSCs, promoting their migration to the injured site, secretion of different matrix components, and excessive deposition of ECM. This results in damage to liver function, morphological changes in the liver parenchyma, and formation of fibrous cords or scars, thus generating liver fibrosis. However, hepatic fibrosis is reversible, and the deposition of ECM can be regulated. The regression of hepatic fibrosis is often accompanied by apoptosis, aging, or inactivation of HSCs and degradation of the ECM (Zhao and Chen, 2019). Activated HSCs are factors in the pathogenesis of hepatic fibrosis, suggesting that HSCs may be used as therapeutic targets to interfere with the intracellular signal pathway when the root cause of a recurrent or chronic injury is unknown. Such molecular biology techniques may include reversing or blocking DNA hypermethylation to inhibit HSC activation and proliferation, promoting HSC apoptosis, aging, or inactivation, and promoting the degradation of ECM to reverse liver fibrosis.

DNA methylation via catalysis by DNA methyltransferase (DNMT) is mediated by a selective covalent bond between a CpG island 5-cytosine and the methyl group provided by S-adenosylmethionine to form 5 mC (Kong et al., 2014). DNA methylation is regulated by two mechanisms. Firstly, DNA that is unmethylated on both strands is methylated, called de novo methylation, which prevents transcription factors from binding to genes, resulting in transcriptional repression. Secondly, one of the strands of DNA in a double strand has been methylated and the other unmethylated strand is methylated, called maintenance methylation. Methylated DNA is recognized by a protein called the methyl-CpG-binding domain (MBD), which recruits other proteins to sites, such as histone deacetylases and other chromatin remodeling factors that can modify histones, to form dense, inactive heterochromatin, thereby inhibiting gene transcription. Gene promoters contain one or more clusters of CpG islands, and most promoters are in the non-methylated state, while the gene body is usually in the methylated state (Ooi et al., 2007) (Figure 1A). Notably, although DNA methylation of CpG islands is clearly associated with transcriptional repression, the function of DNA methylation in CG-deficient promoters remains unclear. Typically, promoter hypermethylation silences gene expression, whereas hypomethylation upregulates gene expression, and overall promoter hypermethylation is negatively correlated with gene expression (Liang Y. et al., 2013). In contrast, gene body hypermethylation is positively associated with active transcription, which regulates splicing and represses the activity of transcription units (codons, promoters, or transposons) within genes, and the function of gene body methylation is currently unknown (Shen and Laird, 2013; Sun et al., 2018).

There are five members of the DNMT family, including three active enzymes, including DNMT1 which is responsible for maintaining the DNA methylation status during DNA replication, and DNMT3a and DNMT3b which mediate de novo methylation of CpG islands to generate new epigenetic marks (Han et al., 2020). During the differentiation of HSCs into fibroblasts, approximately 400 DNA sites (including DNMT3a and DNMT3b) undergo methylation, resulting in over 20% DNA methylation (including hypomethylation and hypermethylation), which is related to gene transcriptional activation or repression.

Methyl-CpG-binding protein 2 (MeCP2) is a transcriptional repressor that specifically binds to methyl-CpGs and represses transcription from methylated gene promoters, or is a complex member of DNMT1 involved in DNA methylation maintenance (Lao et al., 2010). MeCP2 binds to the methyl-CpG sequence in the promoter region of peroxisome proliferator-activated receptor gamma (PPARγ), regulates the repressive H3K9me3 modification enzymes, and inhibits PPARγ transcription initiation and transcription of the PPARγ downstream coding region. Furthermore, MeCP2 promotes enhancer of zeste homolog 2 expression, activates HSCs, and increases collagen secretion in vitro and in vivo (Tahiliani et al., 2009) (Figure 1B). The PPARγ gene is involved in the regulation of adipogenesis, maintenance of the quiescent state in HSCs, and the non-fibrotic phenotype (Huang et al., 2019). Thus, PPARγ gene silencing is necessary for HSC activation. Conversely, MeCP2 also acts as a transcriptional activator (Mellen et al., 2012). MeCP2 actively regulates the expression of absent small or homeotic 1 (ASH1) during HSC transdifferentiation and promotes the transcription of classic profibrotic genes (including COL1A1 and TGF-β1) (Perugorria et al., 2012), coupled with the upregulation of multi-fiber genes (Mou et al., 2022), which ultimately aggravates fibrosis. Additionally, HSCs isolated from MeCP2-knockout mice display decreased expression of myofibroblast marker genes (such as α-smooth muscle actin [SMA] and COL1A1) compared with that in controls, and MeCP2-knockout mice are protected from carbon tetrachloride (CCl₄)-induced liver fibrosis (Mann et al., 2010). MeCP2 is involved in the maintenance of DNA methylation, and silencing or knocking down the MeCP2 gene promotes PPARγ transcription, inhibits HSC activation, and alleviates the progression of liver fibrosis. Therefore, MeCP2 and DNA methylation may provide the molecular mechanism for permanent activation and fibrosis of fibroblasts in the liver.

Smad proteins are a class of transcriptional coordinators that must interact with other DNA-binding proteins to regulate the transcription of target genes. The Smad family of proteins is divided into three categories: receptor-activated or pathway-restricted Smad (R-Smad), common pathway-restricted Smad (co-Smad), and inhibitory Smad (I-Smad). Smad2/Smad3, a downstream factor of Smad signaling, is considered a key regulator of TGF-β signaling in tissue fibrogenesis (Yao et al., 2012), and more importantly, Smad7 is a potential major transcriptional repressor of HSC activation and liver fibrosis in vitro and in vivo, regulating Smad2/Smad3 phosphorylation (Xu et al., 2016). Firstly, TGF-β promotes hepatic fibrosis by inducing HSCs synthesis of TIMPs to inhibit ECM degradation. Secondly, TGF-β promotes fibrosis progression by activating downstream activating mediators, namely, Smad2/Smad3 phosphorylation, which translocate Smad2/Smad3 to the nucleus and then bind to pro-fibrotic DNA sequences that depend on Smad3 to function, promoting the expression of fibrotic proteins, such as COL1A1, α-SMA and epithelial calmodulin E-cadherin (Masszi and Kapus, 2011). At the same time, phosphorylated Smad2/Smad3 positively feeds back into the TGF-β pathway, exacerbating the development of liver fibrosis. This process is negatively regulated by the inhibitory Smad7 (Peng et al., 2022). Bian et al. (2014) reported that silencing DNMT1 increased Smad7 expression and reduced Smad2/Smad3 phosphorylation, significantly reduces TGF-β1-induced HSC activation. DNA methylation is involved in the reduction of Smad7 expression during HSC activation. Besides, overexpression of Smad7 in rats with common bile duct ligation-induced hepatic fibrosis completely blocked TGF-β signaling and protected against liver injury, as evidenced by inhibition of Smad2/Smad3 phosphorylation, blocking HSC activation and leading to reduced COL1A1 expression. Moreover, Smad7 also abrogated the TGF-β-dependent proliferation of HSCs. Smad7 promotes HSC activation and liver fibrosis through epigenetic suppression of DNA methylation/low expression. smad7 is protective and Smad3 is pathogenic. Although α-SMA expression was not reduced by Smad7, the actin cytoskeleton’s fibrillar structure was destroyed when stained with anti-alpha-SMA antibodies (Dooley et al., 2003; Dooley et al., 2008). These results may help us comprehend the role of Smad7 inactivation in liver fibrosis and open the path for further research into its potential targets in the development of treatment approaches.

PTEN is a tumor suppressor gene that negatively regulates proliferation, survival, cell cycle, adherent spots and cell migration, mainly through PI3K-dependent and independent mechanisms. PTEN can also exert inhibitory functions through its protein phosphatase activity. In addition to influencing tumorigenesis, epigenetic processes play a key role in fibrogenesis and fibrosis. When TGF-β1 secretion is increased in the liver, the ERK pathway is activated, which promotes HSC activation and ECM secretion (Li et al., 2013). PTEN inhibits the ERK signal transduction pathway via protein tyrosine phosphatase activity and inhibits fibrosis. Moreover, the downregulation or loss-of-function of the PTEN gene leads to the accumulation of phosphatidylinositol-3,4,5-triphosphate, subsequently enhancing phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) and ERK activity, increasing mitogen signaling and/or decreasing apoptosis, and ultimately leading to liver fibrosis (Yang et al., 2015). PTEN promoter hypermethylation/low expression or deletion has been observed in TGFβ-induced activated HSC-T6 cells in vitro as well as in a CCl₄-induced mouse hepatic fibrosis model (Guan et al., 2022), which is mediated by DNMT1 (Zhu et al., 2020; Song H. et al. 2021; Guan et al., 2022). Therefore, targeting PTEN or DNMT, via silencing the DNMT1 gene or using DNMT inhibitors to prevent PTEN hypermethylation and expression deficiency, and negatively regulate the AKT/ERK pathway, thereby inhibiting HSC activation and alleviating liver fibrosis.

PTCH1 protein is a component of the hedgehog (Hh) signaling pathway (Bragelmann et al., 2021). The Hh signaling pathway is closely related to tissue homeostasis, cell proliferation, differentiation, apoptosis, and migration, and plays a key role in cell growth, differentiation, and animal embryonic development. Furthermore, the Hh signaling pathway is associated with the activation of HSCs. When the Hh protein is absent, PTCH1 binds to its ligands, and activated PTCH1 inhibits smoothened (Smo), thereby reducing Smo activity and inhibiting the downstream signaling pathways. When PTCH1 binds to the Hh protein, PTCH1 is inhibited, which relieves the inhibitory effect of PTCH1 on Smo and activates Smo. This in turn activates the transcription factors Gli1 and Smad3 and expression of Ptch, Wnt, epidermal growth factor, and other target genes, and promotes the secretion of TGF-β1, thus activating HSCs and increasing secretion of COL1A1 and α-SMA (Yang et al., 2013). PTCH1 expression is related to its promoter methylation level, which affects Hh signaling pathway expression. Firstly, in vitro activation of HSCs and CCl₄-induced liver fibrosis models in mice showed that PTCH1 affects HSC activation through the Gli1 and Smad3 signaling pathways. When PTCH1 is hypermethylated, PTCH1 expression is downregulated and HSCs are activated (Yang et al., 2022), while ALKBH5 upregulates PTCH1 expression and improves or alleviates liver fibrosis (Chen et al., 2012). Second, deletion of ALKBH5 was reported to be associated with worsening clinical liver fibrosis in collected clinical liver fibrosis samples. It was confirmed that ALKBH5 expression was significantly lower in human liver fibrosis tissues in mRNA, protein, and immunohistochemical staining compared to controls, and that increased expression of COL1A1 and α-SMA was also consistent with the severity of liver fibrosis detected with Sirius red and Masson trichrome staining (Yang et al., 2022). And hepatic myofibroblasts with MeCP2 siRNA knockdown expressed more PTCH1 mRNA and protein (Yang et al., 2013). These data suggest that DNA methylation and MeCP2 may provide the molecular mechanism for silencing PTCH1. Hh signaling pathway and PTCH1 gene hypermethylation are closely associated with cell proliferation and liver fibrosis, and these findings may be applied to the diagnosis and treatment of patients with liver fibrosis.

The Ras gene is a proto-oncogene that is present in several human cells. The encoded Ras protein is involved in cell proliferation, differentiation, and cytoskeleton construction. In healthy cells, the RAS protein is in an inactive state. When the RAS protein binds to GTP in an activated state, the downstream Ras-Raf-MEK-ERK signaling pathway is abnormally activated, and excessive proliferation signals are transmitted, leading to uncontrolled cell proliferation and the development of tumors (Chen K. et al., 2021). The RASAL1 gene is a tumor suppressor gene that encodes the RASAL1 protein, a member of the Ras-GAP family with GTPase activity and converts active RAS-GTP to inactive RAS-GDP, regulating normal cell growth, differentiation and proliferation (An et al., 2020). There is evidence that hypermethylation is the main mechanism for downregulating RASAL1 gene expression and is associated with fibrotic diseases (Mann et al., 2010). and that epigenetic RASAL1 silencing leads to fibroblast activation and fibrogenesis, similar to the ability of cancer cells to proliferate in a growth factor-independent manner following RASAL1 silencing (Kolfschoten et al., 2005; Jin et al., 2007). Moreover, siRNA knockdown of the MeCP2 gene in HSC-T6 cells inhibits the Ras signaling pathway, resulting in upregulation of RASAL1 mRNA and protein expression in myofibroblasts and suppression of HSC activation and proliferation (Mann et al., 2010). It was demonstrated that the promoter of the methylated RASAL1 gene binds to MeCP2 to repress RASAL1 transcriptional expression and maintain an active RAS-GTP state. According to Bechtel’s research, the low expression of RASAL1 in mice renal fibrogenesis was caused by hypermethylation of the RASAL1 promoter, which is mediated by DNMT1 (Bechtel et al., 2010). Tao et al. (2011) demonstrated that the methylation inhibitor DAC reversed the loss of RASAL1 expression during HSCs proliferation, increasing RASAL1 expression and inhibiting α-SMA expression. This suggests that the hypermethylated RASAL1 gene plays a role in perpetuating fibroblast activation through the imprinting pathway of fibroblast activation and ultimately fibrogenesis.

PTGIS is a member of the CYP8 family that catalyzes the conversion of prostaglandin H2 to prostacyclin I2 (PGI2) (Yu et al., 2017). Both PTGIS and PGI2 exert inhibitory effects on tumor proliferation (Khatun and Ray, 2019; An et al., 2020). PTGIS gene methylation is mediated by the methyltransferases DNMT1 and DNMT3b. The expression of PTGIS is decreased in colon cancer, but increased after the application of the methylation inhibitor DAC, indicating that methylation of the PTGIS gene contributes to the reduction in PTGIS gene expression (Cheng et al., 2021). Pan et al. (2018) found that the promoter of the PTGIS gene was detected to be hypermethylated and under-expressed in TGFβ1-activated HSC-T6 and a CCl₄-induced liver fibrosis mouse model, whereas enforced expression of PTGIS in vitro and in vivo could counteract the activation of HSCs and even cause apoptosis, thereby alleviating liver fibrosis. This has been confirmed by detecting reduced protein and mRNA expression levels of COL1A1 and α-SMA and downregulation of serum ALT/AST levels in activated HSC-T6 cells and primary HSCs isolated from a liver fibrosis mouse model. DNA methylation of PTGIS plays an important role in the progression of liver fibrosis and activation of HSCs, implying that targeting PTGIS has a therapeutic potential ability to treat liver fibrosis.

Notably, PTGIS expression is elevated in the early stages of CCl₄-induced liver fibrosis mice models only to be downregulated at a later stage (Pan et al., 2018). Cebola et al. (2015) found that PTGIS misregulation leads to the accumulation of pro-inflammatory signals. Furthermore, most types of liver injury damage epithelial cells, which leads to the release of inflammatory cytokines such as TGF-β1, IL-6, and TNF (Pellicoro et al., 2014), followed by activation of HSCs by TGF-β1. Therefore, elevated PTGIS expression in the early stages may be attributed to its positive feedback on the inflammatory response. It suggests that interventions for inflammation in addition to methylation aspects are important in the treatment of liver fibrosis.

SUN2, is an inner nuclear membrane protein with an evolutionarily conserved Sad1/UNC-84 homology (SUN) domain at the C-terminus of the protein (Turgay et al., 2010) and is a key component of the connection between the nuclear skeleton and cytoskeleton complex, highly conserved in all eukaryotes and widely expressed in various organs and tissues (Hsieh et al., 2014). SUN2 is also a novel anticancer drug candidate with the ability to inhibit the proliferation and migration of cancer cells and promote their apoptosis. Chen et al. (2018) found that enforced expression of SUN2 inhibited the activation of HSCs and exerted antifibrotic effects in TGF-β1-activated HSC-T6 cells. And in CCl₄-induced liver fibrosis mice, DNMT3b mediates hypermethylation of the SUN2 gene at CpG sites, leading to a reduction in SUN2 expression, induction of HSC activation, and liver fibrosis. Additionally, Lei et al. (2012) found that overexpression of SUN2 alleviates excessive DNA damage in SUN1/2-knockout mouse embryonic fibroblasts. Moreover, SUN2 is necessary for maintaining genomic stability, and DNA damage plays an important pathogenic role in liver fibrosis. SUN2 deficiency induces DNA damage and HSC activation, leading to liver fibrosis. Therefore, hypermethylation of the SUN2 gene mediates the decrease in SUN2 expression in liver fibrosis. Inhibiting DNMT3b and upregulating SUN2 expression may maintain gene stability and reduce the damage caused by fibrosis.

The PSTPIP2 gene is located on chromosome 18 and belongs to the Pombe Cdc15 homology protein family (Yang Y. et al., 2018). PSTPIP2 influences cell proliferation, apoptosis, and inflammatory cytokine secretion, and plays an important role in tumor autoimmunity and other diseases (Chitu et al., 2012). In the progression of liver fibrosis, epigenetic mechanisms are key factors that control the phenotype of macrophages. Hypermethylation of PSTPIP2 is mediated by the methyltransferases DNMT3a and DNMT3b in LPS-induced RAW264.7 cells (Yang Y. et al., 2018). By secreting cytokines and chemokines that stimulate HSCs, activated hepatic macrophages promote liver fibrosis (Friedman, 2008; Cohen-Naftaly and Friedman, 2011). The expression of PSTPIP2 is significantly decreased after partial methylation of PSTPIP2. PSTPIP2 gene overexpression inhibits the expression of classical macrophage (M1) markers by inhibiting signal transducer and activator of transcription 1 (STAT1) activity. Furthermore, PSTPIP2 overexpression promotes STAT6 activity which enhances the expression of alternatively activated macrophage (M2) markers, decreases M1/M2 expression. And PSTPIP2 is enriched in M2-type macrophages, which produce many anti-fibrotic factors, such as IL-10, much more than the small number of fibrotic factors, such as TGF-β and IL-13, that are produced, reducing the inflammatory response and improving liver fibrosis. In mouse liver macrophages isolated from a CCl₄-induced mouse liver fibrosis model, the expression of PSTPIP2 is significantly decreased after partial methylation of PSTPIP2(57). Xu et al. (2022) reported that DNMT3a, a major regulator of PSTPIP2 expression, directly binds to the PSTPIP2 promoter, resulting in PSTPIP2 hypermethylation and low expression, and that silencing DNMT3a significantly restored ethanol-induced low expression in mouse hepatic macrophages. Furthermore, PSTPIP2 may be a potentially critical factor in regulating macrophage polarization in hepatic fibrosis. Thus, inhibition of PSTPIP2 methylation provides a promising approach for therapeutic interventions to prevent or treat liver fibrosis, liver inflammation and related diseases.

The human septin family contains 14 genes (SEPT1-SEPT14), encoding dozens of different septin proteins. Among them, SEPT9 encodes a GTP-binding protein, which plays a role in cytokinesis, intracellular material transport, cell cycle regulation, and apoptosis (Ivanov et al., 2021). Wu et al. (2017) found that SEPT9 is hypermethylated in TGF-β1-treated mouse HSCs and CCl₄-treated mouse liver, and SEPT9 protein expression is significantly reduced, leading to increased ECM accumulation and aggravated fibrosis compared with that in controls. This process can be antagonized by methylation inhibitors silencing DNMT3a and SEPT9 overexpression, thereby reducing liver fibrosis, including upregulation of apoptosis-related proteins in myofibroblasts, and reduction of TGF-β1-induced expression of α-SMA and COL1A1. Li et al. (2022) demonstrated that DNMT1 can also mediate methylation of SEPT9. These results say that SEPT9 methylation is a molecular mechanism of liver fibrosis and is significantly correlated with early diagnosis and prognosis of the disease (Xie et al., 2022; Zhao et al., 2022). Whether the methylation of SEPT9 gene in peripheral blood can also be used for the diagnosis and treatment of liver fibrosis in the future needs to be further investigated.

Spp 1, also referred to as osteopontin, is a ubiquitously expressed secreted phosphoglycoprotein isolated from the mineralized bone matrix and produced by microvascular endothelial cells, fibroblasts, inflammatory cells, and muscle cells (De Luca et al., 2003). SPP1 is a potential oncogenic factor, and is found in tissues, body fluids, and cells under physiological conditions (Stemberger et al., 2014). Silencing of SPP1 inhibits the PI3K/AKT signaling pathway, negatively regulating the ability of various signaling pathways to control cell proliferation, migration, and metabolism (Zhu and Su, 2021). Spp1 expression is increased during many tissue injury repair processes. For example, a reduction in collagen fibers, matrix degradation, and failure of incision healing are observed in a skin incision model in Spp1-knockout mice, suggesting a role for Spp1 in wound repair processes (Call et al., 2008). In Protein-Protein Interaction (PPI) network construction and core gene screening, the modules that include CTGF, TIMP1, SPP1, COL3A1, and other genes are located in the core of the network, which is mainly involved in ECM synthesis, and fibroblast proliferation and transdifferentiation (Heinemeier et al., 2012; Kovacic et al., 2012). Komatsu et al. (2012) analyzed DNA methylation in the liver tissue of rats with CCl₄-induced liver fibrosis and demonstrated that hypomethylation/high expression of the Spp1 gene activates the PI3K/AKT pathway, inducing HSC activation and ECM secretion. The methylation level of the Spp1 gene promoter region is negatively correlated with its expression. Unlike most well-known genes, the hypomethylation/high expression of the SPP1 gene is closely related to the progression of liver cancer and liver fibrosis (Chen et al., 2019; Song Z. et al., 2021), while in the known liver fibrosis-related genes we described all undergo hypermethylation/low expression, promoting fibrosis development. These findings suggest that hypomethylation of the Spp1 gene and increased secretion of COL1A1 and α-SMA contribute to the development of liver fibrosis. Whether hypermethylation of SPP1 gene can treat liver fibrosis needs to be further investigated.

The use of nucleoside analogs is affected by pharmacokinetics, chemical instability, adverse toxic effects, and lack of selectivity. Methylation inhibitors are small molecules that are not incorporated into the DNA and may eliminate many defects associated with nucleoside analogs (Fandy, 2009). In the past two decades, non-nucleoside methylation inhibitors have emerged. Based on their mechanisms of action, these inhibitors are divided into three categories: DNA binders, S-adenosylmethionine (SAM) antagonists, and a subset of drugs with unknown mechanisms.

Procainamide and hydralazine are FDA-approved drugs for cardiovascular disease therapy and exhibit DNA demethylation activity in cloned T cell lines (Cheng et al., 2019). Procainamide downregulates hypermethylation of the anti-inflammatory gene IL27RA in the lung, ear, nose, and throat tissues by inhibiting DNMT1 and 5 mC, thus treating multiple organ failure caused by endotoxin (Shih et al., 2016). Procainamide also reverses hypermethylation of pi-class glutathione S-transferase P1 in tumor tissues and inhibits tumor cell growth (Li et al., 2021). Both hydralazine and procainamide bind to GC-rich regions to induce demethylation, which activates tumor suppressor genes that have been inactivated by hypermethylation to exert anti-tumor activity (Zhao et al., 2012). Although these drugs are chemically stable, present few toxic side effects, and can be administered orally, they require high doses to exert their demethylation effects, which exceed clinically safe doses (Uddin and Fandy, 2021).

RG108 (N-phthalyl-L-tryptophan) is a selective DNMT1 inhibitor and the first small-molecule non-nucleoside DNMT inhibitor to induce demethylation effects in cancer cells (Wu et al., 2019). Using an indole moiety, RG108 binds to the SAM binding site of DNMT1, competitively occupying the SAM site and inhibiting DNA methylation progression. In vitro studies in the colon cancer cell line HCT116 reveal that RG108 reactivates the expression of tumor suppressor genes, including p16, TIMP3, and SFRP1, via promoter demethylation (Brueckner et al., 2005). Although RG108 does not demonstrate cytotoxicity in HCT116 cells at high concentrations, RG108 activity fails to reverse methylation at the three CpG sites as determined by DNA pyrosequencing within the LINE-1 sequence of leukemia cells compared with the effects of DAC (Carraway et al., 2020). Moreover, high concentrations of RG108 slightly reduce methylation (by 3%–5%). In these experiments, DAC served as a positive control and induced a 25% reduction in methylation at 100-fold lower concentrations than RG108, indicating a large difference in activity between RG108 and DAC(80).

Curcumin, a polyphenolic natural compound derived from Curcuma longa, exerts anti-inflammatory, antioxidant, and anti-cancer effects through a variety of epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNA (Jin et al., 2022). Combining curcumin derivatives and nucleoside DNMT inhibitors may maximize their effects on gene expression, which is more effective than the function of curcumin alone to induce DNA methylation changes via the nuclear factor-kappa B, PI3K, Ras, and other signaling pathways (Chen et al., 2007). Curcumin enhances the demethylation effect of DAC on related tumor suppressor genes, upregulates the expression of tumor suppressor genes, and inhibits tumor cell growth (Chen J. Q et al., 2021). Despite extensive research on curcumin and its analogs, no related drugs are currently approved by the FDA for clinical applications. As curcumin is considered a pan-assay interference compound that does not act on the target but shows false positive results, and presents low bioavailability and rapid metabolism, any future clinical relevance of curcumin remains controversial (Uddin and Fandy, 2021).

Lastly, shikonin is a natural naphthoquinone extracted from the shikonin plant, a traditional Chinese medicine, that upregulates the transcriptional activity of tumor suppressor p16 by inhibiting the expression of DMNT1 (Jang et al., 2015; Boulos et al., 2019). Isofitsularin-3, an alkaloid natural product isolated from Aplysina aerophoba, moderately inhibits DNMT1) (Florean et al., 2016; Shen and Luo, 2020; Wong, 2021). Moreover, psammaplin, a group of natural compounds derived from the South China Sea sponge Pseudoceratina purpurea, inhibits both DNMT and histone deacetylase (HDAC) with low toxicity (Liu et al., 2017). Epigallocatechin gallate, a major component of green tea, non-covalently binds to the catalytic active site of DNMT, thereby inhibiting DNA methylation of related oncogenes (Ni et al., 2011; Yang et al., 2020). As DNMT plays an important role in DNA methylation, DNMT inhibition may block the hypermethylation and downregulate related genes (such as PTGIS, PTEN, and Smad2/Smad3), inhibit the activation and proliferation of HSCs, inhibit the expression of α-SMA and COL1A1 in vitro, and delay liver fibrosis.